Chemed’s Q2 earnings drop Tuesday, with market expecting a strong 7.5% revenue jump—up from last year’s 3.8%—after they surprised with a solid Q1 performance. Analysts are bullish, and with peers like Tenet and UnitedHealth also beating targets, Chemed’s 11.1% stock surge this month hints at momentum. Can they deliver again and keep investors excited?

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/430796edd255dc65

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av, eller tillsammans med, Poddtoppen.